The trial, which started in February, is evaluating whether the vaccine generates a strong immune response in those aged between 6 and 17.
While the trial has been paused, Professor Andrew Pollard from the University of Oxford ruled out safety concerns with the trial itself, the BBC reported on Wednesday.
What the scientists are waiting for is more information, said the report.
"Whilst there are no safety concerns in the paediatric clinical trial, we await additional information from the MHRA (Medicines and Healthcare products Regulatory Agency) on its review of rare cases of thrombosis/thrombocytopaenia that have been reported in adults, before giving any further vaccinations in the trial," Pollard was quoted as saying by the BBC.
The suspension of the trial of the vaccine comes after a European Medicines Agency (EMA) official, speaking in a personal capacity, said there could be a link between the coronavirus vaccine developed by
Meanwhile, UK Prime Minister
He said that the current advice of the country's medicines regulator, is to "keep going out there, get your jab, get your second jab" and "we need to keep that going".
The vaccines are already "starting to have a beneficial effect on the trajectory of the disease", said Johnson, noting the falling number of cases and deaths in the country.
SEE ALSO:
For the third consecutive day, a new unicorn is born from India as PharmEasy joins the billion dollar club
Barbeque Nation bears the brunt of an uncertain future – shares list at 2% discount
You need to do full KYC for mobile wallets too – but you can store twice the amount of money